Skip to content
    Inve.money
    Earnings calls

    Senores Pharmaceuticals Limited concall ledger

    Every earnings call for SENORES — management tone, guidance, KPIs and promise tracking, quarter by quarter.

    SENORES · 5 transcripts · Healthcare · latest Q4 FY26

    Senores Pharmaceuticals Limited has 5 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.

    Q3 FY26Published 20 Jan 2026Call held 20 Jan 2026

    SENORES Q3 FY26 Earnings Call Transcript & Analysis

    Consolidated Revenue₹175 cr+64% YoYConsolidated EBITDA₹54 cr+86% YoYConsolidated EBITDA Margin30.9%Consolidated PAT₹32 cr+85% YoY

    Consolidated Revenue ₹175 cr (+64% YoY); Consolidated EBITDA ₹54 cr (+86% YoY); Consolidated EBITDA Margin 30.9%. Consolidated revenue grew 64% YoY to INR175 crores in Q3 FY26.

    Read full transcript & analysis
    Q3 FY26Published 20 Jan 2026Call held 20 Jan 2026

    SENORES Q3 FY26 Earnings Call Transcript & Analysis

    Consolidated Revenue₹175 cr+64% YoYConsolidated EBITDA₹54 cr+86% YoYConsolidated EBITDA Margin30.9%Consolidated PAT₹32 cr+85% YoY

    Consolidated Revenue ₹175 cr (+64% YoY); Consolidated EBITDA ₹54 cr (+86% YoY); Consolidated EBITDA Margin 30.9%. Consolidated income for Q3 FY26 grew 64% YoY to INR175 crores.

    Read full transcript & analysis
    Q1 FY26Published 24 Jul 2025Call held 24 Jul 2025

    SENORES Q1 FY26 Earnings Call Transcript & Analysis

    Consolidated Revenue₹138 cr+72% YoYConsolidated EBITDA₹34 cr+60% YoYConsolidated EBITDA Margin24.8%Consolidated PAT₹21 cr+95% YoY

    Consolidated Revenue ₹138 cr (+72% YoY); Consolidated EBITDA ₹34 cr (+60% YoY); Consolidated EBITDA Margin 24.8%. Consolidated revenue grew by 72% YoY to INR 138 crores.

    Read full transcript & analysis